Perampanel (PER) has gained a current approval for monotherapy of treating focal-onset seizures with or without secondarily generalized seizures, and as an adjuvant therapy with concomitant antiepileptic drug (AED) for primary generalized seizures in patients aged older than 4 years. The recent studies on its monotherapy have become a breakthrough by recognizing its vast potential in clinical practices. This systematic review is aimed to correlate all the studies on monotherapy to validate the efficacy and safety profile of the drug.
No takes yet. Share an insight, caveat, or question.
BSV Raju (2022) studied this question.
Synapse has enriched 5 related papers. Consider them for comparative context: